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We investigated the effects of different windows of testosterone propionate (TP) treatment during foetal and neonatal life in female rats to
determine whether and when excess androgen exposure would cause disruption of adult reproductive function. Animals were killed
prepubertally at d25 and as adults at d90. Plasma samples were taken for hormone analysis and ovaries serial sectioned for morphometric
analyses. In prepubertal animals, only foetalCpostnatal and late postnatal TP resulted in increased body weights, and an increase
in transitory, but reduced antral follicle numbers without affecting total follicle populations. Treatment with TP during both
foetalCpostnatal life resulted in the development of streak ovaries with activated follicles containing oocytes that only progressed to
a small antral (smA) stage and inactive uteri. TP exposure during foetal or late postnatal life had no effect upon adult reproductive
function or the total follicle population, although there was a reduction in the primordial follicle pool. In contrast, TP treatment during
full postnatal life (d1–25) resulted in anovulation in adults (d90). These animals were heavier, had a greater ovarian stromal
compartment, no differences in follicle thecal cell area, but reduced numbers of anti-Mullerian hormone-positive smA follicles when
compared with controls. Significantly reduced uterine weights lead reduced follicle oestradiol production. These results support the
concept that androgen programming of adult female reproductive function occurs only during specific time windows in foetal and
neonatal life with implications for the development of polycystic ovary syndrome in women.
Reproduction (2012) 143 21–33Introduction
Androgens have been shown to play important roles in
ovarian function not only acting as substrates for
oestradiol (E2) production in preovulatory follicles but
also by modulating ovarian function both directly and
indirectly. Studies on both sheep (Steckler et al. 2007,
2009, Hogg et al. 2011) and primates (Abbott et al. 1998,
2002, 2007) have shown that inappropriate exposure to
androgens in foetal life results in reduced or absent
ovarian function in adult life and may provide models for
polycystic ovary syndrome (PCOS) in women (Abbott
et al. 2007, Franks 2009). Up to 22% of women may have
polycystic ovaries (PCO), but only around 5–10% of
women develop the syndrome (PCOS), associated with
increased androgenisation, weight gain and infertility
(Franks et al. 2006). Androgen receptors (ARs) are
expressed in the oocyte, granulosa and thecal cells ofq 2012 Society for Reproduction and Fertility
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distribution, and reproduction in any medium, provided the original work is properlythe follicle, are highest in small follicles and expression is
developmentally regulated during follicle development
being down-regulated by FSH and LH (see Drummond
2006, Walters et al. 2008). Global knockout of the AR in
female mice leads to reduced fertility with reduced
numbers of antral follicles and increased granulosa cell
(GC) apoptosis (Hu et al. 2004, Shiina et al. 2006, Walters
et al. 2008). More refined studies on GC-specific
AR-knockout mice suggest that these reproductive
defects are attributed to lack of AR expression in GCs
(Sen & Hammes 2010). Androgens promote mouse
follicular development in vitro through effects on
methylation and up-regulation of the FSH receptor
expression in conditions that are marginal for follicle
growth (Hillier & Tetsuka 1997, Murray et al. 1998a,
1998b). In contrast, excess androgens correlated with
poor oocyte fertilisation and developmental ratesDOI: 10.1530/REP-11-0239
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on and Fertility’s Re-use Licence which permits unrestricted non-commercial use,
cited.
Table 1 Body and organ weights and plasma LH levels across TP
treatment groups in prepubertal animals (d25).
TP treatment group
Body
weight
(g)
Uterus
weight
(mg)
FSH
(ng/ml)
LH
(ng/ml)
Control oil nZ12 52G2 28G4 2.63G0.3 6.5G1.0
Foetal nZ8 51G1 28G2 1.68G0.3 3.7G0.7
Full postnatal nZ6 56G3 137G32† 2.98G0.8 !0.8‡
FoetalCpostnatal nZ5 81G3‡ 121G19‡ 2.10G0.3 9.6G2.3
Late postnatal nZ5 77G6† 202G6‡ 1.43G0.5 !0.8‡
Results are meanGS.E.M. and were analysed by Student’s unpaired t-test
(†P%0.01; ‡P%0.001).
22 V Tyndall and others(Anderiesz & Trounson 1995, Xia & Younglai 2000) and
can induce atresia in developing follicles (Billig et al.
2003). Thus, it appears that in vitro the effects of
androgens on follicle development in established follicle
populations is dependent on the stage of follicle
development and the ratio of androgens to E2, while in
the longer term AR expression in GCs is essential for
normal follicle development (Drummond 2006).
Several studies on rats have demonstrated that
continuous exposure of postpubertal animals to steroid
hormones, either via regular s.c. dosing or continuous
release pellet implant, produces an anovulatory pheno-
type in these animals (Faiman et al. 1988, Beloosesky
et al. 2004, Misugi et al. 2006, Alexanderson et al. 2007,
Baravalle et al. 2007, Manneras et al. 2007, 2008,
Abbott et al. 2009). Such models recapitulate some
of the features of PCOS in women who have increased
ovarian and stromal volume, increased thecal
17a-hydroxylase (17aOH) activity (Nelson et al. 1999,
2001) and high plasma concentrations of LH, testoster-
one and androstenedione (Welt et al. 2005, Franks et al.
2006, Fulghesu et al. 2007). Sheep (Steckler et al. 2007)
and non-human primate models of PCOS (Faiman et al.
1988, Abbott et al. 2009) focus on the adult con-
sequences of foetal programming by administering
androgen (usually testosterone) during foetal life at a
time when germ cells first begin to form primordial
follicles. However in rodents, this treatment period of
exposure corresponds to early postnatal life (McNeilly
et al. 2000, Pepling & Spradling 2001, Pepling 2006).
Thus, previous studies on the role of androgens in
rodents that concentrate on acute effects of androgens on
follicle development do not address the question of the
potential for long-term androgen-induced reprogram-
ming of the ovary during foetal and/or neonatal life on
adult reproductive function.
Here, we extend previous research into foetal and
neonatal programming of male rats by testosterone
propionate (TP; Welsh et al. 2008, 2010) by investigating
the reproductive consequences of foetal and neonatal TP
exposure in female rats. These investigations aim to
determine which windows of neonatal TP treatment
induce an altered reproductive phenotype in the adult
females and to what extent, if any, the resulting
phenotype mimics human reproductive pathophysiology
such as PCOS.Results
Effects of different windows of TP exposure upon female
rat reproductive physiology
Immature females
In immature rats (d25), both foetalCpostnatal and just
late postnatal TP treatment resulted in a significant
(P!0.001) increase in body weight. Exposure to TP
during any postnatal window resulted in a significantReproduction (2012) 143 21–33(P!0.05 and P!0.01) increase in uterine weight and
significant (P!0.001) reduction in plasma LH levels as
expected, due to aromatisation of the TP to E2 (Table 1).
Adult females
TP administration in all treatment groups except the late
postnatal group (d15–24) resulted in an absence of
vaginal opening. In adult animals at d90, TP treatment in
full postnatal, foetalCpostnatal and late postnatal
treatment groups resulted in a significant (P!0.05 to
P!0.001) increase in body weight and reduced uterine
weights (Table 2). No differences in E2 or LH levels were
observed across TP treatment groups. FSH levels were
significantly reduced in animals from the foetal
Cpostnatal TP treatment group (P%0.05), and levels
were undetectable (P!0.001) in the full postnatal TP
treatment group (Table 2).
Mean adult ovarian weight was significantly reduced
(P%0.01) in animals from the full postnatal TP treatment
group due to a lack of corpora lutea (CL; Fig. 1C and
Table 2). Ovaries from the foetal and late postnatal TP
treatment groups appeared morphologically normal with
comparable numbers of CL (data not shown) to control
ovaries (Fig. 1A, B and E). FoetalCpostnatal TP ovaries
were very small and severely underdeveloped,
embedded in fat and could not be weighed accurately.
Upon histological examination (Fig. 1D), foetal
Cpostnatal TP ovaries appeared as underdeveloped
‘streak’ ovaries set within the gonadal fat pad (Fig. 2B
and D). These ovaries had significantly (P!0.01) fewer
anti-Mullerian hormone (AMH)-positive follicles com-
pared with controls (controls: 72G20; foetalCpostnatal
testosterone: 8G2).Neonatal androgen exposure leads to a reduction in the
pool of primordial follicles in the adult but not in the
prepubertal rat
Compared with oil-treated controls, there were no
significant differences in total follicle numbers in ovaries
from any treatment groups in both immature d25 and
adult d90 rats, except for a significant (P!0.05)
reduction at d90 in the foetalCpostnatal group
(Fig. 3B). In immature rats, both full and late postnatalwww.reproduction-online.org
Table 2 Body and organ weights and hormone concentrations across TP treatment groups in adult animals (d90).
TP treatment group
Body
weight (g)
Ovary
weight (mg)
Uterus
weight (mg) E2 (pg/ml) FSH (ng/ml) LH (ng/ml)
Control oil nZ5 213G9 95G4 433G52 12.1G2.1 1.8G0.1 5.9G1.0
Foetal nZ3 228G7 NA 470G75 16.9G1.2 2.1G0.7 4.7G1.0
Full postnatal nZ4 318G6‡ 59G5† 307G15† 4.2G1.3 !0.8‡ 2.2G0.9
FoetalCpostnatal nZ5 309G5‡ NA 158G35‡ 9.7G2.9 1.3G0.4‡ 4.3G1.0
Late postnatal nZ5 239G6† 80G5 247G38‡ 9.3G3.2 1.6G0.2 5.1G1.2
Results are meanGS.E.M. and were analysed by Student’s unpaired t-test (†P%0.01; ‡P%0.001). NA, not available.
Neonatal androgen and adult ovarian function 23treatment groups had a significantly (P%0.05) greater
proportion of transitory and significantly (P!0.05)
reduced proportions of antral follicles. Adults had a
significantly (P!0.01) reduced proportion of primordial
follicles in postal TP treatment groups compared with
controls. Furthermore, adults from the foetalCpostnatal
group also had a significantly reduced number of follicles
(P%0.05) and proportion of antral follicles (P%0.001),
since most follicles from this treatment group did not
reach large antral (lgA) stage (Fig. 2B and C).Assessment of adult anovular ovaries following full
postnatal treatment
Full postnatal TP ovaries were morphologically cystic in
appearance (Figs 1 and 4–7). To quantify this cystic
phenotype, average antrum size of follicles containing
an oocyte with a visible nucleus was measured in every
tenth section (Fig. 4C). Full postnatal TP led to a
significant (P%0.001) increase in antrum size compared
with controls.
Follicular functional status in both control and full
postnatal TP-treated animals was measured using semi-
quantitative analysis of AMH (Fig. 4) and aromatase
expression (Fig. 5). Follicles expressing these proteins
were counted and categorised in every tenth serial
section. Although reduced, no significant difference in
the total number of AMH-positive follicles was found
(Fig. 4D), but there was a significantly (P%0.01) reduced
proportion of AMH-positive small antral (smA) follicles in
full postnatal TP-treated ovaries (Fig. 4E). Compared with
controls, the number of aromatase-positive antral follicles
was significantly (P%0.05) greater in full postnatal
TP-treated animals (Fig. 5D). However, no differences
were found in the proportions of lgA follicles staining
intensely, weakly, or not at all for aromatase (Fig. 5E).
The thecal cell layer and stromal compartment area
were measured in serial tenth sections of both control
and postnatal TP-treated animals using immunohisto-
chemistry (IHC) for 17aOH (Fig. 6) and 3b-hydroxy-
steroid dehydrogenase (3bHSD; Fig. 7) respectively.
There was no difference in the proportion of 17a-
OH-positive follicles (Fig. 6D) or in thecal thickness and
the total area occupied by thecal cells (Fig. 6F–G)
between control and full postnatal TP animals. In
addition, there was no difference in the correlationswww.reproduction-online.orgbetween individual thecal area and follicle diameter in
either treatment group (Fig. 6E). After correction for the
area of the CLs in the control ovaries, the 3bHSD-
positive stromal compartment (Fig. 7C and D) of full
postnatal TP ovaries was significantly (P%0.05) larger
than that of control ovaries and occupied a significantly
(P%0.001) greater proportion of ovarian area.Discussion
As outlined in the Introduction section, androgens can
have profound positive and negative effects on ovarian
follicle development as well as providing the essential
substrate for E2 production by preovulatory follicles.
Chronic administration of steroids or steroidogenic
inhibitors during postnatal life in the rat have been
assessed to determine whether any altered reproductive
phenotype in the adult resembles that found in
women with PCOS. Steroids used include testosterone
(Beloosesky et al. 2004), DHEA (Anderson & Lee 1997,
Anderson et al. 1997), E2 valerate (Brawer et al. 1986,
Rosa et al. 2003), DHT and letrozole (Manneras et al.
2007) while single bolus injection of testosterone or E2
on or just after the day of birth resulted in a PCO-like
phenotype in the adult animal (Barraclough 1961,
Brawer et al. 1978, Ota et al. 1986, Grossmann et al.
1987, Alexanderson et al. 2007). However, relatively
few rodent models have fully examined the reproductive
phenotype in the adult animal and contrasted it with the
clinical situation (Ota et al. 1986, Misugi et al. 2006,
Abbott et al. 2007). Follicle formation is a continuum in
both humans and sheep, occurring during mid gestation
(McNatty et al. 2000, Childs et al. 2010). In the rat,
follicle formation occurs in the first few days after birth
(Schindler et al. 2010), equating to approximately mid-
gestation in humans. In this study, rats were exposed to
TP in various time windows, including postnatal only or
foetalCpostnatal life. Thus, it is reasonable in our
current study to assume that the exposure to TP and,
potentially, any E2 that may be converted from the TP
(Picon et al. 1985), would occur over a similar time
period of follicle formation and development as in the
other non-rodent models of PCOS, namely sheep
(Steckler et al. 2007) and primates (Abbott et al. 2009).Reproduction (2012) 143 21–33
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Figure 1 Ovarian morphology of adult d90 animals
from (A) control, (B) foetal, (C) postnatal,
(D) foetalCpostnatal and (E) late postnatal TP
treatment groups. Images A–C and E taken at !2
magnification, bar represents 500 mm. Image D
taken at!4 magnification, bar represents 200 mm.
24 V Tyndall and othersFoetal TP has no discernable effects upon
the female rat
Foetal TP did not affect folliculogenesis or fertility in
immature or adult animals, as evidenced by the presence
of normal numbers of CL in the adult animals, and
normal follicle numbers and proportions at both ages.
Immature and adult body weights were normal, and
gonadotrophin and E2 levels were comparable to those
seen in controls at each stage of investigation for this TP
treatment group. These findings corroborate previous
investigations into the effects of foetal TP upon female
reproductive development (Slob et al. 1983). It is worth
noting that there may be strain differences in the
response to foetal androgen exposure as foetal TP
administration in Sprague–Dawley (SD) rats in one
study reduced both immature and adult body weight
(Wolf et al. 2002, 2004). Foetal TP-treated female rats
develop masculinised features of the urogenital tract, for
example, an increased anogenital distance, as described
in the original papers upon which these studies were
based (Welsh et al. 2008, 2010).Reproduction (2012) 143 21–33Postnatal TP treatment leads to changes in ovarian
follicle composition in the immature animal
At d25, in late postnatal TP and foetalCpostnatal TP
(streak ovary) treatment groups, a higher proportion of
activating transitory follicles and lower proportion of
smA follicles was observed, with no effects upon total
follicle numbers at this age. These results demonstrate
the mitogenic effects of testosterone upon folliculogen-
esis, whereby androgens stimulate GC proliferation of
smaller newly activated transitory and primary follicles
as shown in graft experiments of ruminant follicles pre-
exposed to testosterone and transplanted into chick
ovaries; the grafts were shown to selectively increase the
proportion of growing primary follicles (Qureshi et al.
2008). The same graft study found androgens to have a
protective effect upon follicle survival, which is at odds
with the reduced proportion of smA follicles found in the
late postnatal and foetalCpostnatal TP treatment groups
of the current study. In the rat, ovarian AR expression is
reduced in GCs of FSH-responsive follicles (Tetsuka et al.
1995) and other studies on rats have shown thatwww.reproduction-online.org
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Figure 2 Follicular functional status in control
(nZ5) and foetalCpostnatal TP-treated adult d90
animals (nZ4), assessed by AMH serial staining.
AMH staining is shown in ovaries from control
(A,C) and postnatal TP-treated (B,D) animals at
(A,B)!2 magnification, barZ500 mm, and (C,D)
!40 magnification, barZ50 mm.
Neonatal androgen and adult ovarian function 25exogenous androgen administration at the later stages of
gonadotrophin-dependent folliculogenesis can facilitate
follicular atresia (Drummond 2006, Honnma et al.
2006). Indeed, the smA follicles present in the immature
rat ovary do not express sufficient aromatase in GCs for
the production of E2 (Mahesh et al. 1987). Thus, in the
current study, TP likely acts to promote GC atresia in
more advanced follicles, which would account for the
reduction in smA follicle proportions within these TP
treatment groups at d25.TP treatment after birth up to d15 leads to weight gain
in adult animals
Significant weight gain was observed at d25 in immature
foetalCpostnatal and late postnatal TP-treated animals
and in adults within all postnatal TP treatment groups. It
is possible that this weight gain would affect metabolic
function, but this was not assessed in this study. Other
studies have only examined prenatal oestrogen (Roland
et al. 2010) and glucocorticoids (Cottrell & Seckl 2009),
which can induce metabolic dysfunction in mice and
rats. In the current study, the increase in body weight was
much less in the late postnatal group in the adults. This
indicates that the window of postnatal androgen
exposure which can produce a metabolic phenotype
extends for at least 14 days after birth, but the effect
appears to be less if treated only in the late postnatal
period from d15 to 25. Furthermore, these findings
extend results from other studies in which regular
neonatal administration of androgens (testosterone;
Nilsson et al. 1998; DHT: Alexanderson et al. 2007) or
aromatase inhibitors (Letrozole; Manneras et al. 2007)
has been shown to program weight gain and increasedwww.reproduction-online.orgadiposity in adult animals. Recently, it has been
suggested that oestrogen receptors, implying oestrogen
action, exert a stronger metabolic programming effect
than ARs (Beloosesky et al. 2004). In this study, we do not
know to what extent, if at all, the TP would have been
converted to E2 in the neonatal treatment periods, and
this will require further investigation.FoetalCpostnatal TP treatment leads to the formation
of underdeveloped streak ovaries
TP administered during both foetal and postnatal life
resulted in underdeveloped streak ovaries within both
immature and adult animals, which by d90 of life had
fewer follicles, fewer activated AMH-expressing follicles
and consequential lower circulating E2 levels with
significantly reduced uterine weights. Secretion of
AMH by GCs of growing follicles is known to inhibit
further follicle activation (Durlinger et al. 2002, Rey et
al. 2003, Pellatt et al. 2010). It is thus conceivable that
the lower expression of AMH in the streak ovaries might
allow unimpeded follicular recruitment and subsequent
atresia. This could account for the reduction in follicle
numbers within the adult animals by d90.
The presence of streak ovaries at both d25 and d90 also
implicates a combined effect of late foetal and early
postnatal TP exposure, given that no effect was found in
foetal TP-treated animals and a different effect was
observed in the full postnatal TP-treated animals. Streak
ovaries have been associated with FSH receptor (Levallet
et al. 1999) and BMP15 (Rossetti et al. 2009) mutations
and is associated with an autoimmune response in
neonatally thymectomised mice (Scalzo & Michael
1988). The potential role of the thymus is unknown.Reproduction (2012) 143 21–33
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Figure 3 Follicle count results across TP treatment
groups; total follicle numbers are shown for
(A) immature d25 animals and (B) adult d90 animals
and were analysed by Student’s t-test. Follicle
proportions are shown for (C) immature animals and
(D) adult animals and were analysed by two-way
ANOVA. Values are expressed as the meanGS.E.M.
(*P%0.05; **P%0.01; ***P%0.001).
26 V Tyndall and othersHowever, the involvement of alterations in FSH receptor
function was not examined in the current study, while
BMP15 does not appear to play a significant role in rodent
follicle formation or development (Yan et al. 2001).
Neonatal E2 exposure in rodents prevents germ cell nest
breakdown in the ovary (Kezele & Skinner 2003, Jefferson
et al. 2006) and effects involving ESR1 (ERa), ESR2 (ERb)
and the membrane-bound estrogen receptor (Chen et al.
2009). It is possible that in our study, circulating E2
resulting from the placental or foetal and neonatal
ovarian aromatisation of TP (Picon et al. 1985) and/or
levels of TP acting purely as an androgen in animals
exposed as foetuses were high enough to persist into early
neonatal life and increase the sensitivity of the postnatal
animal to further androgen exposure. This notion is
supported by another study in which TP administered to
pregnant SD rats during the late foetal period (e17–e18)
had a priming effect upon female animals, leading to the
masculinisation of female behaviour and physiology in
animals, which subsequently received a small postnatal
dose of 5 mg TP (Hoepfner & Ward 1988). Animals in the
foetal and foetalCpostnatal TP treatment group were
cross fostered to untreated dams that had recently littered
to avoid pup death (Wolf et al. 2002, Welsh et al. 2008,
2010). Evidence suggests that inadequate maternal care,
in addition to differences in litter size during the rodent
neonatal period, can affect hypothalamic–pituitary axis
development (Champagne et al. 2003, Roma et al.
2007). Cross fostering of certain litters (foetal and foetal
Cpostnatal TP) and not others (full postnatal and late
postnatal TP) may have had an additional environmental
effect upon endocrine development and function in
animals from different litters, potentially accounting for
the differences in ovarian morphology and reproduc-
tive dysfunction observed between treatment groups.Reproduction (2012) 143 21–33However, in the previous studies, using the same time
windows of TP treatment did not identify any significant
endocrine or phenotypic differences after cross
fostering compared with normal controls (Welsh et al.
2008, 2010).Postnatal TP treatment leads to changes in ovarian
follicle composition in the adult animal
One unexpected finding of these investigations was the
increase in the proportion of primordial follicles
consistently observed in all animals that received TP
postnatally. This result is at odds with previous
observation of an increase in primary follicles and
decrease in the primordial follicle pool in ovaries of
women with PCOS (Webber et al. 2003). At present, it is
unclear clear how neonatal TP affects the rat follicle pool
in this way, although recent research in mice has shown
that oestrogen acting via both ESR1 and ESR2 can affect
primordial follicle populations by inhibiting oocyte
apoptosis before birth and preventing germ cell nest
breakdown after birth (Chen et al. 2009). Thus,
aromatisation of TP into E2 within the neonate could
account for the effects seen, as aromatase activity has
been shown in the neonatal pituitary (Carretero et al.
2003) and ovaries (Picon et al. 1985) of female rats.
Additionally, reduced primordial follicle recruitment
could play a part in the conservation of the primordial
pool documented in the current study.The postnatally androgenised rat as a PCOS model
Full postnatal TP (d1–25) induced a PCOS-like pheno-
type in the adult rat and was evaluated as a PCOS model.www.reproduction-online.org
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Figure 4 Follicular functional status in control (nZ5) and postnatal TP-treated adult d90 animals (nZ4), assessed by AMH serial staining and antrum
size. AMH staining is shown in ovaries from control and postnatal TP-treated animals at (A)!2 magnification, barZ500 mm, and (B) !20
magnification, barZ100 mm. Follicles were analysed based on (C) antrum size, shown as a scatter plot with lines indicating the meanGS.E.M., (D) the
number of AMH-positive follicles and (E) which follicles of different sizes stained positively for AMH follicles. (D–E) Values are expressed as the
meanGS.E.M. (**P%0.01; ***P%0.001).
Neonatal androgen and adult ovarian function 27Animals from this treatment group had reduced ovarian
weights due to anovulation and lack of CL in addition to
low uterine weights that, as a bioassay for oestrogens in
the rat, indicate low oestrogen levels. However, it should
be noted that plasma E2 levels were comparable to
controls in this group. An unexpected effect was that
plasma FSH levels were undetectable, and LH levels
were low in this treatment group. Given that the bioassay
for E2 levels indicated reduced levels (though when
measured plasma E2 was within normal range), it seems
reasonable to expect that this would result in an increase
in both LH and FSH secretion (McNeilly et al. 2003).
The fact that this has not occurred suggests that the
TP treatment has altered the negative feedback
regulation of gonadotrophin secretion and will require
further investigation.
Histological examination of ovaries from full postnatal
TP-treated animals showed that they were anovular, with
large fluid filled antral follicles apparent on subjective
inspection. The reduction in the proportion of smA
AMH-positive follicles in animals given postnatal TP
may have contributed towards a larger mean number of
antral follicles staining positive for aromatase found in
adjacent sections and supports the idea that the
functional status of follicles was altered, particularly
given the low levels of FSH. This is supplemented by the
fact that follicles within the ovaries of adult postnatalwww.reproduction-online.orgTP-treated animals had larger mean antrum sizes.
Further studies will be required to determine whether
the altered ovarian phenotype that recapitulates some of
the features of PCOS are related only to long-term effects
on the ovary of TP exposure in the prenatal period or to
altered gonadotrophin levels with or without a presumed
metabolic effect related to weight gain.
No difference was observed between ovaries from the
full postnatal TP-treated animals and control animals with
regard to the status of the theca. Indeed, the thecal
compartment was of a comparable size, surrounded a
comparable number of follicles and the 17aOH stained
area was similar between control and TP-treated animals.
Given that the theca only develops around follicles as they
grow beyond the primary stage (Young & McNeilly 2010),
these results suggest that in the rat, at least there is no long-
term effect on any thecal precursor cells in the stroma in
adult life. In contrast, a novel finding of this study was the
increased amount and proportion of 3bHSD-positive
stroma found in full postnatal TP-treated animals, which
further recapitulates clinical observations in women with
PCOS (Fulghesu et al. 2007, Welt et al. 2005). As no
differences in circulating gonadotrophins were observed
in adult full postnatal TP-treated animals, this would
indicate that this increased stromal compartment could be
due to primary programming of non-thecal precursor
cells, as hypothesised by other investigators (Franks 2009).Reproduction (2012) 143 21–33
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Figure 5 Follicular functional status in control (nZ5)
and postnatal TP-treated adult d90 animals (nZ4)
assessed by aromatase serial staining and antrum size.
Aromatase staining is shown in ovaries from control
and postnatal TP-treated animals at (A)!2 magni-
fication, barZ500 mm, and (B)!20 magnification,
barZ100 mm, and (C) at different staining intensities;
(D) the number of follicles expressing aromatase and
(E) the proportions of follicles expressing either strong,
weak or negative aromatase levels. Values are
expressed as the meanGS.E.M. (*P%0.05).
28 V Tyndall and othersIn conclusion, the results from the foetalCpostnatal TP
group, in agreement with the findings of other studies
(Hoepfner & Ward 1988), demonstrate that foetal TP may
reduce the sensitivity threshold to neonatal testosterone
exposure in female animals, providing one explanation
for the failure of normal ovarian development observed in
this treatment group. Exposure to TP during the first
25 days of life additionally led to a significant increase in
both immature and adult body weight through an as yet
unknown mechanism. Finally, TP administration during
the first 15 days of life resulted in a PCOS-like phenotype
in the female: overweight, anovulatory and with larger
than normal follicles as well as an increased ovarian
stromal compartment. However, these phenotypic
changes occur in the absence of the abnormalities ofReproduction (2012) 143 21–33FSH and LH typically associated with PCOS and suggest
that neonatal TP exposure in the rat at least does not
provide an adequate model for all aspects of PCOS.Materials and Methods
Animals and treatments
Wistar rats were bred and maintained in the University of
Edinburgh animal facility under standard conditions with
licensed approval from the University Ethical Review Process
and a UK Home Office Project Licence. Animals had access to
water and a soy-free breeding diet made available ad libitum
(SDS; Dundee, Scotland). Matings were timed and presence of
a vaginal plug designated embryonic day 0.5 (e0.5). TP
treatment regimes are summarised in the original paperwww.reproduction-online.org
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Figure 6 17a-Hydroxylase (17aOH) staining in
ovaries from (A) control (i; nZ5) and postnatal
(ii; nZ4) TP-treated adult d90 animals, barZ
500 mm. Theca interna 17aOH staining at
(B)!20 magnification, barZ100 mm, and (C)!40
magnification. (D) The proportions of follicles
expressing 17aOH in their theca interna were
classified and analysed by two-way ANOVA with
Bonferroni post hoc test, (E) thecal thickness was
correlated with follicle diameter for both control
and TP-treated animals and analysed by linear
regression (control R2Z0.875, postnatal R2Z
0.883). A Fisher-Z transformation tested for
differences between these two correlations; control
nZ43 follicles and postnatal TP nZ44 follicles
yieldedPZ0.876. Differences in (F) thecal thickness
and (G) proportional 17aOH-positive area were
analysed by Student’s t-test. Bar graph values are
expressed as the meanGS.E.M.
Neonatal androgen and adult ovarian function 29(Welsh et al. 2010). Briefly, for foetal TP treatment, pregnant
dams were injected s.c. with 20 mg/kg TP in 0.4 ml corn oil
daily between e14.5 and 21.5. To avoid foetal mortality that
can be brought about by dystocia (Welsh et al. 2008), foetuses
from TP-treated dams were delivered by caesarean and cross-
fostered to untreated dams that had delivered within the last 6 h
(Welsh et al. 2010). For postnatal TP treatment, pups were
injected with 20 mg/kg TP every 3 days (d) in three different
treatment groups: i) late postnatal TP treatment, from d15 to 24;
ii) foetalCpostnatal TP treatment, from foetal e14.5 to e21.5,
then from d1 (the day after birth) to 24; and iii) full postnatal TP
treatment, from d1 to 24. At least three litters were used per
treatment group. Control animals received the same volume of
oil as for each treatment period and were treated in foetal
and neonatal life. This treatment had previously been shown
to have no effect when compared with untreated controlswww.reproduction-online.org(Welsh et al. 2010). Animals were killed by inhalation of
carbon dioxide and cervical dislocation on d25 (immature) and
d90 (adult). Body and organ weights were documented and a
blood sample collected by cardiac puncture for hormone
analysis. Ovaries and uteri were fixed in Bouins for 6 h,
transferred into 70% ethanol and processed into paraffin wax
using standard methods.Ovarian IHC
One ovary from each animal was serial sectioned (5 mm
thickness) and mounted onto permafrost slides for analysis
using multiple IHC markers. Every tenth section was used for
each set of IHC analysis. Sections were stained with haema-
toxylin and eosin (H&E) for follicle count analysis, or DAB IHC
was performed as described previously (McNeilly et al. 2000).Reproduction (2012) 143 21–33
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Figure 7 3b-Hydroxysteroid dehydrogenase
(3bHSD) staining in ovaries from (A) control
(nZ5), barZ500 mm, and (B) postnatal TP-treated
adult d90 animals (nZ4), barZ200 mm. Mural
granulosa, theca and CL 3bHSD staining was
accounted for, and (C) 3bHSD-positive stromal
area was measured in mm2, and (D) taken as a
proportion of ovarian area (minus CL area in
controls). Values are expressed as the mean
GS.E.M. (*P%0.05; ***P%0.001).
30 V Tyndall and othersPrimary antibodies were diluted in normal serum: mouse anti-
aromatase at 1:50 ml (Gift – Prof. N Groome, Oxford Brookes
University); goat anti-AMH at 1:500 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA: MIS C-20); rabbit anti-17aOH at 1:500
(Gift– Dr D Hales Southern Illinois University); and rabbit anti-
3bHSD at 1:250 (Gift–Prof. I Mason, University of Edinburgh).
Slides were counterstained with haematoxylin, dehydrated
through alcohols and xylene and mounted in pertex (Histolab,
Gothenburg, Sweden) for analysis.Morphological and stereological analysis
Every tenth section of each ovary was H&E stained and
examined at !20 and !40 magnification under a light
microscope. Follicles were counted and classified according
to a previously published method, allowing for a realistic
estimate of follicle proportions with minimal data manipulation
(Hirshfield & Midgley 1978, McNeilly et al. 2011). Only
follicles containing a visible oocyte nucleus were included in
the count, and these were classified based on their GC
morphology. A layer of flat squamous GCs indicated a
primordial follicle. Two or more cuboidal GCs indicated a
transitory follicle. If two or less than two layers of cuboidal GCs
were present around the oocyte, the follicle was primary and if
more than two layers of cuboidal GCs were present around the
oocyte, the follicle was secondary. If there were more than two
layers of cuboidal GCs and an antrum had formed, the follicle
was antral. In subsequent analyses, antral follicles with clear
cumulus–oocyte complex formation and O5 GC layers were
classified as lgA follicles and those with !4 GC layers were
classified as smA follicles.
The number of cells per follicles expressing AMH or
aromatase as well as their staining intensity was used to
semi-quantitatively assess follicle morphology. Morphometric
analysis of antrum size, 17aOH staining and 3bHSD staining
was completed using stereological equipment comprising an
Olympus BH-2 microscope fitted with a Prior automatic stage
(Prior Scientific Instruments Ltd., Cambridge, UK). For 17aOH
and 3bHSD, stained area below 10 mm2 was not included,Reproduction (2012) 143 21–33in order to discount any background. CL and areas of non-
specific staining were also masked using Image-Pro Plus
version 6.2 with Stereologer-Pro 5 plug-in software (Media
Cybernetics UK, Wokingham, Berkshire, UK), as published
previously (McNeilly et al. 2011). Figure images were taken
with a Provis AX70 (Olympus Optical, London, UK)
microscope fitted to a Canon DS6031 camera (Canon Europe,
Amsterdam, The Netherlands).Hormone RIA and ELISA
Plasma E2 was assayed following solvent extraction using a
sensitive RIA modified for mouse plasma as described
previously (McNeilly et al. 2000, 2011). All samples were
assayed in a single assay with a minimum detectable
concentration of 4.6 pg/ml and an intra-assay coefficient of
variation of!8%. The in-house ELISAs using the same general
method were performed to assess plasma FSH and LH. Capture
antibody diluted in buffer (50 ml of 0.2 M sodium bicarbonate–
carbonate buffer) was adsorbed onto plastic plates (Nunc
Biologicals, Thermo Scientific, Epsom, Surrey, UK) overnight.
Plates were then washed with wash buffer (0.1 M Tris–HCl pH
7.5) and then washed with assay buffer (Tris–HCl, pH 7.5)
containing 0.001% Tween20, 1% BSA (Sigma A3294) and
0.1% bovine-g-globulin for a further 1 h. After a further wash,
5 ml standards, quality controls and unknown samples were
added to the plate in duplicate and incubated with 95 ml assay
buffer overnight at 4 8C. Between steps, plates were washed
using 200 ml wash buffer and dried and all antibodies/samples
were diluted in assay buffer.
For the FSH ELISA, mouse FSH (NIDDK AFP5308D;
Dr A Parlow, Harbor-UCLA Medical Center, Torrance, CA,
USA) was used as standard (range 0.78–50 ng/ml) with
anti-human FSH MAB (4 mg/ml; MedixBiochemica 6602,
BiosPacific, Inc., Emeryville, CA, USA) used as capture antibody.
The second antibody was biotinylated rabbit anti-rat a-subunit
IC1 (NIDDK AFP66P99860; 5 mg/ml) and anti-rabbit HRP
conjugate (1:10 000; Thermo Scientific #31458) was used
for signal detection.www.reproduction-online.org
Neonatal androgen and adult ovarian function 31For the LH ELISA, mouse LH (NIDDK AFP5306A) was used
as standard (range 0.78–25 ng/ml) with anti-bovine LH chain
MAB (2 mg/ml; 518B7; Gift – Dr J Roser, UCLA) used as capture
antibody. The second antibody was biotinylated anti-human
LH MAB (MedixBiochemica 5303, Kauniainen, Finland;
1 mg/ml) and Amdex streptavidin-HRP conjugate (1:10 000;
GE Healthcare, Chalfont St Giles, Bucks, UK) RPN4401Vq was
used for signal detection.
After a final wash cycle, both ELISAs were visualised with
100 ml 30,50,50-tetramethylbenzidine micro-well peroxidase blue
chromogen solution for 30 min (KPL). In both assays, oxidation
was stopped by addition of 6% phosphoric acid. Absorbance was
read using a plate spectrophotometer as l 450 nm minus l
620 nm to eliminate any background from the results that were
analysed using AssayZap (Biosoft, Cambridge, UK).Statistical analysis
All data shown are expressed as meanGS.E.M. and analysed
using GraphPad Prism 5 (GraphPad Software, Inc., San Diego,
CA, USA). Two-way ANOVA was performed between any
grouped data, for example, follicle counts, with a Bonferroni
post hoc analysis to assess for specific in-group differences.
Unless otherwise states, a two-tailed unpaired Student’s t-test
was used to evaluate the differences between rodent treatment
groups in all other circumstances. To determine the correlation
between two sets of data, the Pearson product–moment
correlation (PPMC) was used. To assess for differences between
two correlation coefficients, a Fisher r-to-Z transformation was
performed and applied to the sample correlation coefficients (r)
calculated by PPMC. In Graphpad Prism, a P value for a Fisher
transformation was then calculated to test for the significant
differences between two sets of overlapping correlative data.Declaration of interest
The authors declare that there is no conflict of interest that
could be perceived as prejudicing the impartiality of the
research reported.Funding
This work was funded by the Medical Research Council
(G00007.01) to A S McNeilly.Acknowledgements
We thank Judy McNeilly, Linda Nicol, Ian Swanston, Nancy
Evans, Mike Millar and Mark Fisken for excellent technical help.References
Abbott DH, Dumesic DA, Eisner JR, Colman RJ & Kemnitz JW 1998
Insights into the development of polycystic ovary syndrome (PCOS) from
studies of prenatally androgenized female rhesus monkeys. Trends in
Endocrinology and Metabolism 9 62–67. (doi:10.1016/S1043-2760
(98)00019-8)www.reproduction-online.orgAbbott DH, Dumesic DA & Franks S 2002 Developmental origin of
polycystic ovary syndrome – a hypothesis. Journal of Endocrinology 174
1–5. (doi:10.1677/joe.0.1740001)
Abbott DH, Dumesic DA, Levine JE, Dunaif A & Padmanabhamn V 2007
Animal models and fetal programming of the polycystic ovary syndrome.
In Contemporary Endocrinology: Androgen Excess Disorders in Women,
IV, pp 259–272. Ed. R Azziz. Totawa, NJ: Humana Press.
Abbott DH, Tarantal AF & Dumesic DA 2009 Fetal, infant, adolescent and
adult phenotypes of polycystic ovary syndrome in prenatally androgen-
ized female rhesus monkeys. American Journal of Primatology 71
776–784. (doi:10.1002/ajp.20679)
Alexanderson C, Eriksson E, Stener-Victorin E, Lystig T, Gabrielsson B,
Lonn M & Holmang A 2007 Postnatal testosterone exposure results in
insulin resistance, enlarged mesenteric adipocytes, and an atherogenic
lipid profile in adult female rats: comparisons with estradiol and
dihydrotestosterone. Endocrinology 148 5369–5376. (doi:10.1210/en.
2007-0305)
Anderiesz C & Trounson AO 1995 The effect of testosterone on the
maturation and developmental capacity of murine oocytes in vitro.
Human Reproduction 10 2377–2381.
Anderson E & Lee GY 1997 The polycystic ovarian (PCO) condition:
apoptosis and epithelialization of the ovarian antral follicles are aspects of
cystogenesis in the dehydroepiandrosterone (DHEA)-treated rat model.
Tissue & Cell 29 171–189. (doi:10.1016/S0040-8166(97)80017-1)
Anderson E, Lee GY & O’Brien K 1997 Polycystic ovarian condition in the
dehydroepiandrosterone-treated rat model: hyperandrogenism and the
resumption of meiosis are major initial events associated with
cystogenesis of antral follicles. Anatomical Record 249 44–53. (doi:10.
1002/(SICI)1097-0185(199709)249:1!44::AID-AR6O3.0.CO;2-F)
Baravalle C, Salvetti NR, Mira GA, Lorente JA & Ortega HH 2007 The role
of ACTH in the pathogenesis of polycystic ovarian syndrome in rats:
hormonal profiles and ovarian morphology. Physiological Research 56
67–78.
Barraclough CA 1961 Production of anovulatory, sterile rats by single
injections of testosterone propionate. Endocrinology 68 62–67. (doi:10.
1210/endo-68-1-62)
Beloosesky R, Gold R & Almog B 2004 Induction of polycystic ovary by
testosterone in immature female rats: modulation of apoptosis and
attenuation of glucose/insulin ratio. International Journal of Molecular
Medicine 14 207–215.
Billig H, Furuta I & Hsueh AJ 2003 Oestrogens inhibit and androgens
enhance ovarian granulosa cell apoptosis. Endocrinology 133
2204–2212. (doi:10.1210/en.133.5.2204)
Brawer JR, Naftolin F, Martin J & Sonnenschein C 1978 Effects of a single
injection of estradiol valerate on the hypothalamic arcuate nucleus and
on reproductive function in the female rat. Endocrinology 103 501–512.
(doi:10.1210/endo-103-2-501)
Brawer JR, Munoz M & Farookhi R 1986 Development of the polycystic
ovarian condition (PCO) in the estradiol valerate-treated rat. Biology of
Reproduction 35 647–655. (doi:10.1095/biolreprod35.3.647)
Carretero J, Va´zquez G, Rubio M, Blanco E, Juanes JA, Pe´rez E, Burks D &
Va´zquez R 2003 Postnatal differentiation of the immunohistochemical
expression of aromatase P450 in the rat pituitary gland. Histology and
Histopathology 18 419–423.
Champagne FA, Francis DD, Mar A & Meaney MJ 2003 Variations in
maternal care in the rat as a mediating influence for the effects of
environment on development. Physiology & Behavior 79 359–371.
(doi:10.1016/S0031-9384(03)00149-5)
Chen Y, Breen K & Pepling ME 2009 Estrogen can signal through multiple
pathways to regulate oocyte cyst breakdown and primordial follicle
assembly in the neonatal mouse ovary. Journal of Endocrinology 202
407–417. (doi:10.1677/JOE-09-0109)
Childs A, Kinnell HL, Collins CS, Hogg K, Bayne RAL, Green SJ,
McNeilly AS & Anderson RA 2010 BMP signaling in the human fetal
ovary is developmentally regulated and promotes primordial germ cell
apoptosis. Stem Cells 28 1368–1378. (doi:10.1002/stem.440)
Cottrell EC & Seckl JR 2009 Prenatal stress, glucocorticoids and
the programming of adult disease. Frontiers in Behavioral Neuroscience
3 1–9. (doi:10.3389/neuro.08.019.2009)
Drummond AE 2006 The role of steroids in follicular growth. Reproductive
Biology and Endocrinology 4 16–26. (doi:10.1186/1477-7827-4-16)Reproduction (2012) 143 21–33
32 V Tyndall and othersDurlinger ALL, Visser VA & Themmen APN 2002 Regulation of ovarian
function: the role of anti-Mullerian hormone. Reproduction 124
601–609. (doi:10.1530/rep.0.1240601)
Faiman C, Reyes FI, Dent DW, Fuler GB, Hobson WC & Thliveris JA 1988
Effects of long-term testosterone exposure on ovarian function and
morphology in the rhesus monkey. Anatomical Record 222 245–251.
(doi:10.1002/ar.1092220305)
Franks S 2009 Do animal models of polycystic ovary syndrome help to
understand its pathogenesis and management? Yes, but their limitations
should be recognized Endocrinology 150 3983–3985. (doi:10.1210/en.
2009-0652)
Franks S, McCarthy MI & Hardy K 2006 Development of polycystic ovary
syndrome: involvement of genetic and environmental factors. Inter-
national Journal of Andrology 28 278–285. (doi:10.1111/j.1365-2605.
2005.00623.x)
Fulghesu AM, Angioni S, Frau E, Belosi C, Apa R, Mioni R, Xamin N,
Capobianco GP, Dessole S, Fruzzetti F et al. 2007 Ultrasound in
polycystic ovary syndrome – the measuring of ovarian stroma and
relationship with circulating androgens: results of a multicentric study.
Human Reproduction 22 2501–2508. (doi:10.1093/humrep/dem202)
Grossmann R, Diez-Guerra FJ, Mansfield S & Dyer RG 1987 Neonatal
testosterone modifies LH secretion in the adult female rat by altering the
opioid–noradrenergic interaction in the medial preoptic area. Brain
Research 415 205–210. (doi:10.1016/0006-8993(87)90202-2)
Hillier SG & Tetsuka M 1997 Role of androgens in follicle maturation and
atresia. Baillie`re’s Clinical Obstetrics and Gynaecology 11 249–260.
(doi:10.1016/S0950-3552(97)80036-3)
Hirshfield AN & Midgley AR Jr 1978 Morphometric analysis of follicular
development in the rat. Biology of Reproduction 19 597–605. (doi:10.
1095/biolreprod19.3.597)
Hoepfner BA & Ward IL 1988 Prenatal and neonatal androgen exposure
interact to affect sexual differentiation in female rats. Behavioral
Neuroscience 102 61–65. (doi:10.1037/0735-7044.102.1.61)
Hogg K, McNeilly AS & Duncan WC 2011 Prenatal androgen exposure
leads to alterations in gene and protein expression in the ovine fetal
ovary. Endocrinology 152 2048–2059. (doi:10.1210/en.2010-1219)
Honnma H, Endo T, Henmi H, Nagasawa K, Baba T, Yamazaki K,
Kitajima Y, Hayashi T, Manase M & Saito T 2006 Altered expression of
Fas/Fas ligand/caspase 8 and membrane type 1-matrix metalloproteinase
in atretic follicles within dehydroepiandrosterone-induced polycystic
ovaries in rats. Apoptosis 11 1525–1533. (doi:10.1007/s10495-006-
9148-2)
Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, Zhou X, Chao HT, Tsai MY
& Chang C 2004 Subfertility and defective folliculogenesis in female
mice lacking androgen receptor. PNAS 101 11209–11214. (doi:10.1073/
pnas.0404372101)
Jefferson W, Newbold R, Padilla-Banks E & Pepling M 2006 Neonatal
genistein treatment alters ovarian differentiation in the mouse: inhibition
of oocyte nest breakdown and increased oocyte survival. Biology of
Reproduction 74 161–168. (doi:10.1095/biolreprod.105.045724)
Kezele P & Skinner MK 2003 Regulation of ovarian primordial follicle
assembly and development by estrogen and progesterone: endocrine
model of follicle assembly. Endocrinology 144 3329–3337. (doi:10.
1210/en.2002-0131)
Levallet J, Pirjo Pakarinen P & Huhtaniemi IT 1999 Follicle-stimulating
hormone ligand and receptor mutations, and gonadal dysfunction.
Archives of Medical Research 30 486–494. (doi:10.1016/S0188-0128
(99)00058-5)
Mahesh VB, Mills TM, Bagnell CA & Conway BA 1987 Animal models for
study of polycystic ovaries and ovarian atresia. In Regulation of Ovarian
and Testicular Function, 198, pp 237–257. Eds VB Mahesh, DS Dhinsa,
E Anderson & SP Katra. New York: Plenum Press.
Manneras L, Cajander S, Holma¨ng A, Seleskovic M, Lystig T, Lo¨nn M &
Stener-Victorin E 2007 A new rat model exhibiting both ovarian and
metabolic characteristics of polycystic ovary syndrome. Endocrinology
148 3781–3791. (doi:10.1210/en.2007-0168)
Manneras L, Jonsdottir IH, Holma¨ng A, Lo¨nn M & Stener-Victorin E 2008
Low frequency electro-acupuncture and physical exercise improve
metabolic disturbances and modulate gene expression in adipose tissue
in rats with dihydrotestosterone-induced polycystic ovary syndrome.
Endocrinology 149 3559–3568. (doi:10.1210/en.2008-0053)Reproduction (2012) 143 21–33McNatty KP, Quirke LD, Fidler A, Smith P, Heath DA & Tisdall D 2000
Ovarian development: fetus to puberty. In Hormones and Women’s
Health, pp 9–22. Ed. LA Salamonsen. Australia: Harwood Academic
Publishers.
McNeilly JR, Saunders PTK, Taggart M, Cooke HJ & McNeilly AS 2000 Loss
of oocytes in Dazl knockout mice results in maintained ovarian
steroidogenic function but altered gonadotropin secretion in adult
animals. Endocrinology 141 4284–4294. (doi:10.1210/en.141.11.4284)
McNeilly AS, Crawford JL, Taragnat C, Nicol L & McNeilly JR 2003 The
differential secretion of FSH and LH: regulation through genes, feedback
and packaging. Reproduction Supplement 61 463–476.
McNeilly JR, Watson E, Brown Y, Murray AA, Spears N & McNeilly AS
2011 Decreased oocyte DAZL expression results in increased litter size
by modulating FSH-induced follicle growth. Biology of Reproduction 85
584–593. (doi:10.1095/biolreprod.110.086264)
Misugi T, Ozaki K, El Beltagy K, Tokuyama O, Honda K & Ishiko O 2006
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of
DHEA-induced PCOS rats. Gynecologic and Obstetric Investigation 61
208–215. (doi:10.1159/000091496)
Murray AA, Gosden RG, Allison V & Spears N 1998a Effects of androgens
on the development of mouse follicles growing in vitro. Journal of
Reproduction and Fertility 113 27–33. (doi:10.1530/jrf.0.1130027)
Murray AA, Swales AKE, Smith RE, Molinek MD, Hillier SG & Spears N
1998b Follicular growth and oocyte competence in the in vitro cultured
mouse follicle: effects of gonadotrophins and steroids. MHR-Basic
Science of Reproductive Medicine 14 75–83.
Nelson VL, Legro RS, Strauss JF III & McAllister JM 1999 Augmented
androgen production is a stable steroidogenic phenotype of propagated
theca cells from polycystic ovaries. Molecular Endocrinology 13
946–957. (doi:10.1210/me.13.6.946)
Nelson VL, Qin K, Rosenfeldt RL, Wood JR, Penning TM, Legro RS,
Strauss JF III & McAllister JM 2001 The biochemical basis for increased
testosterone production in theca cells propogated from patients with
polycystic ovary syndrome. Journal of Clinical Endocrinology and
Metabolism 86 5925–5933. (doi:10.1210/jc.86.12.5925)
Nilsson C, Niklasson M, Eriksson E, Bjorntorp P & Holmang A 1998
Imprinting of female offspring with testosterone results in insulin
resistance and changes in body fat distribution at adult age in rats.
Journal of Clinical Investigation 101 74–78. (doi:10.1172/JCI1353)
Ota H, Wakizaka A, Fukushima M & Maki M 1986 Enhanced ovarian
gonadotropin receptors in the testosterone-induced polycystic ovary in
rats. Tohoku Journal of Experimental Medicine 148 313–325. (doi:10.
1620/tjem.148.313)
Pellatt L, Rice S & Mason HD 2010 Anti-Mullerian hormone and polycystic
ovary syndrome: a mountain too high? Reproduction 139 825–833.
(doi:10.1530/REP-09-0415)
Pepling ME 2006 From primordial germ cell to primordial follicle:
mammalian female germ cell development. Genesis 44 622–632.
(doi:10.1002/dvg.20258)
Pepling ME & Spradling AC 2001 Mouse ovarian germ cell cysts undergo
programmed breakdown to form primordial follicles. Developmental
Biology 234 339–351. (doi:10.1006/dbio.2001.0269)
Picon R, Pelloux MC, Benhaim A & Gloaguen F 1985 Conversion of
androgen to estrogen by rat fetal and neonatal female gonad: effects of
dbCAMP and FSH. Journal of Steroid Biochemistry 23 995–1000.
(doi:10.1016/0022-4731(85)90058-5)
Qureshi AI, Nussey SS, Bano G, Musonda P, Whitehead SA & Mason HD
2008 Testosterone selectively increases primary follicles in ovarian
cortex grafted onto embryonic chick membranes: relevance to polycystic
ovaries. Reproduction 136 187–194. (doi:10.1530/REP-07-0172)
Rey R, Lukas-Croisier C, Lasala C & Bedecarra´s P 2003 AMH/MIS: what we
know already about the gene, the protein and its regulation. Molecular
and Cellular Endocrinology 211 21–31. (doi:10.1016/j.mce.2003.09.
007)
Roland AV, Nunemaker CS, Keller SR & Moenter SM 2010 Prenatal
androgen exposure programs metabolic dysfunction in female mice.
Journal of Endocrinology 207 213–223. (doi:10.1677/JOE-10-0217)
Roma PG, Huntsberry ME & Riley AL 2007 Separation stress, litter size, and
the rewarding effects of low-dose morphine in the dams of maternally
separated rats. Progress in Neuro-Psychopharmacology & Biological
Psychiatry 31 429–433. (doi:10.1016/j.pnpbp.2006.11.005)www.reproduction-online.org
Neonatal androgen and adult ovarian function 33Rosa ESA, Guimaraes MA, Padmanabhan V & Lara HE 2003 Prepubertal
administration of estradiol valerate disrupts cyclicity and leads to cystic
ovarian morphology during adult life in the rat: role of sympathetic
innervation. Endocrinology 144 4289–4297. (doi:10.1210/en.2003-0146)
Rossetti R, Pasquale ED, Marozzi A, Bione S, Toniolo D, Grammatico P,
Nelson LM, Beck-Peccoz P & Persani L 2009 BMP15 mutations associated
with primary ovarian insufficiency cause a defective production of
bioactive protein. Human Mutation 30 804–810. (doi:10.1002/humu.
20961)
Scalzo CM & Michael SD 1988 Source of high testosterone levels associated
with autoimmune ovarian dysgenesis in neonatally thymectomized B6A
mice. Biology of Reproduction 38 1115–1121. (doi:10.1095/biolre-
prod38.5.1115)
Schindler R, Nilsson E & Skinner MK 2010 Induction of ovarian primordial
follicle assembly by connective tissue growth factor CTGF. PLoS ONE 5
e12979. (doi:10.1371/journal.pone.0012979)
Sen A & Hammes SR 2010 Granulosa cell-specific androgen receptors are
critical regulators of ovarian development and function. Molecular
Endocrinology 24 1393–1403. (doi:10.1210/me.2010-0006)
Shiina H, Matsumoto T, Sato T, Igarishi K, Miyamoto J, Takemasa S,
Sakari M, Takada I, Nakamura T, Metzger D et al. 2006 Premature
ovarian failure in androgen receptor-deficient mice. PNAS 103 224–229.
(doi:10.1073/pnas.0506736102)
Slob AK, den Hamer R, Woutersen PJ & van der Werff ten Bosch JJ 1983
Prenatal testosterone propionate and postnatal ovarian activity in the rat.
Acta Endocrinologica 103 420–427.
Steckler T, Manikkam M, Inskeep EK & Padmanabhan V 2007 Develop-
mental programming: follicular persistence in prenatal testosterone-
treated sheep is not programmed by androgenic actions of testosterone.
Endocrinology 148 3532–3540. (doi:10.1210/en.2007-0339)
Steckler TL, Herkimer C, Dumesic DA & Padmanabhan V 2009
Developmental programming: excess weight gain amplifies the effects
of prenatal testosterone excess on reproductive cyclicity – implication for
polycystic ovary syndrome. Endocrinology 150 1456–1465. (doi:10.
1210/en.2008-1256)
Tetsuka M, Whitelaw PF, Bremner WJ, Millar MR, Smyth CD & Hillier SG
1995 Developmental regulation of androgen receptor in rat ovary.
Journal of Endocrinology 145 535–543. (doi:10.1677/joe.0.1450535)
Walters KA, Allan CM & Handelsman DJ 2008 Androgen action and the
ovary. Biology of Reproduction 78 380–389. (doi:10.1095/biolreprod.
107.064089)www.reproduction-online.orgWebber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K & Franks S
2003 Formation and early development of follicles in the polycystic
ovary. Lancet 362 1017–1021. (doi:10.1016/S0140-6736(03)14410-8)
Welsh M, Saunders PTK, Fisken M, Scott HM, Hutchison GR, Smith LB,
Richard M & Sharpe RM 2008 Identification in rats of a programming
window for reproductive tract masculinization, disruption of which leads
to hypospadias and cryptorchidism. Journal of Clinical Investigation 118
1479–1490. (doi:10.1172/JCI34241)
Welsh M, MacLeod DJ, Walker M, Smith LB & Sharpe RM 2010 Critical
androgen-sensitive periods of rat penis and clitoris development.
International Journal of Andrology 33 e144–e152. (doi:10.1111/j.1365-
2605.2009.00978.x)
Welt CK, Taylor AE, Fox J, Messerlian GM, Adams JM & Schneyer AL 2005
Follicular arrest in polycystic ovary syndrome is associated with deficient
inhibin A and B biosynthesis. Journal of Clinical Endocrinology and
Metabolism 90 5582–5587. (doi:10.1210/jc.2005-0695)
Wolf CJ, Ostby JS, LeBlanc GA & Gray LE Jr 2002 Effects of prenatal
testosterone propionate on the sexual development of male and female
rats: a dose–response study. Toxicological Science 65 71–86. (doi:10.
1093/toxsci/65.1.71)
Wolf CJ, LeBlanc GA & Gray LE Jr 2004 Interactive effects of vinclozolin
and testosterone propionate on pregnancy and sexual differentiation of
the male and female SD rat. Toxicological Science 78 135–143. (doi:10.
1093/toxsci/kfh018)
Xia P & Younglai EV 2000 Relationship between steroid concentrations in
ovarian follicular fluid and oocyte morphology in patients undergoing
intracytoplasmic sperm injection (ICSI) treatment. Journal of Reproduc-
tion and Fertility 118 229–233. (doi:10.1530/reprod/118.2.229)
Yan C, Wang P, DeMayo J, DeMayo FJ, Elvin JA, Carino C, Prasad SV,
Skinner SS, Dunbar BS, Dube JL et al. 2001 Synergistic roles of bone
morphogenetic protein 15 and growth differentiation factor 9 in ovarian
function. Molecular Endocrinology 15 854–866. (doi:10.1210/me.15.6.
854)
Young J & McNeilly AS 2010 Theca – the forgotten cell of the ovarian
follicle. Reproduction 140 489–504. (doi:10.1530/REP-10-0094)
Received 30 June 2011
First decision 17 August 2011
Accepted 19 October 2011Reproduction (2012) 143 21–33
